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ABSTRACT	 	
A simple, rapid, precise, sensitive and reproducible reverse phase high performance liquid 
chromatography (RP-HPLC) method has been developed for the quantitative analysis of Dolutegravir 
and Rilpivirine in pharmaceutical dosage form. Chromatographic separation of Dolutegravir and 
Rilpivirine was achieved on Waters Alliance -2695, by using Luna C18 (250mm x 4.6mm, 5µm) column 
and the mobile phase containing 0.1% OPA & ACN in the ratio of 50:50 v/v. The flow rate was 1.0 
ml/min, detection was carried out by absorption at 245 nm using a photodiode array detector at ambient 
temperature. The number of theoretical plates and tailing factor for Dolutegravir and Rilpivirine were 
NLT 2000 and should not more than 2 respectively. The linearity of the method was excellent over the 
concentration range 10-150 µg/ml and 5-75 µg/ml for Dolutegravir and Rilpivirine respectively. The 
correlation coefficient was 0.999. % Relative standard deviation of peak areas of all measurements 
always less than 2.0. The proposed method was validated according to ICH guidelines. The method was 
found to be simple, economical, suitable, precise, accurate & robust method for quantitative analysis of 
Dolutegravir and Rilpivirine study of its stability.	
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INTRODUCTION	Development	 of	 a	 simple,	 reliable	 and	 accurate	method	for	the	assay	of	Dolutegravir	and	Rilpivirine	tablet	 dosage	 form	 by	 reverse	 phase	 HPLC	 and	validate	 the	 method	 for	 its	 repeatability	 and	reproducibility.	 Dolutegravir	 is	 an	 HIV-1	 antiviral	agent.	 It	 inhibits	 HIV	 integrase	 by	 binding	 to	 the	active	 site	 and	 blocking	 the	 strand	 transfer	 step	 of	
retroviral	DNA	integration	in	the	host	cell.	The	strand	transfer	step	is	essential	in	the	HIV	replication	cycle	and	 results	 in	 the	 inhibition	 of	 viral	 activity.	Dolutegravir	has	a	mean	EC50	value	of	0.5	nM	(0.21	ng/mL)	to	2.1	nM	(0.85	ng/mL)	in	peripheral	blood	mononuclear	cells	(PBMCs)	and	MT-4	cells.		
 
Figure 1: Chemical structure of Dolutegravir Dolutegravir	 (DTG),	 an	 unboosted	 HIV	 integrase	inhibitor	 (INI),	 is	metabolized	 by	UGT1A1	 and	 to	 a	minor	 extent	 by	 CYP3A.	 Renal	 elimination	 of	unchanged	 DTG	 is	 very	 low	 (<	 1%).	 As	 renal	impairment	may	affect	pharmacokinetics	(PK),	even	for	drugs	primarily	metabolized	or	 secreted	 in	bile,	this	study	investigated	the	effect	of	renal	impairment	on	the	PK	of	DTG	Rilpivirine	is	a	non-competitive	NNRTI	that	binds	to	reverse	 transcriptase.	 Its	 binding	 results	 in	 the	blockage	 of	 RNA	 and	 DNA-	 dependent	 DNA	polymerase	activities,	 like	HIV-1	replication.	 It	does	not	present	activity	against	human	DNA	polymerases	α,	 β	 and	 γ.	 Rilpivirine	 binds	 to	 the	 HIV-1	 reverse	
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transcriptase	 (RT)	 and	 its	 flexible	 structure	 around	the	aromatic	rings	allows	the	adaptation	to	changes	in	the	non-nucleoside	RT	binding	pocket.		
 
Figure 2: Chemical structure of Rilpivirine	Rilpivirine	 is	 highly	 protein-bound,	 and	 more	 than	99%	may	be	bound	 to	human	plasma	proteins	 in	 a	concentration-dependent	 manner.31	 Under	 fasting	conditions,	 the	 maximum	 plasma	 concentration	 of	rilpivirine	 (Cmax)	 decreased	 by	 46%	 and	 the	 area	under	 the	 rilpivirine	 plasma	 concentration	 curve	(AUC)	decreased	by	43%.	Similarly,	rilpivirine	Cmax	and	 AUC	 are	 reduced	 by	 50%	 when	 given	 with	 a	protein-rich	nutritional	drink.	32	As	a	consequence,	it	is	 recommended	 to	 take	 rilpivirine	 with	 food	 but	avoid	 taking	 after	 a	 protein-rich	 drink.	 In	 a	 7-day	pharmacokinetic	 study	 of	 oral	 administration	 of	rilpivirine	25	mg,	50	mg,	100	mg,	and	150	mg	once	daily,	 Cmax	was	 generally	 reached	 3–4	 hours	 after	dosing.32	Plasma	concentrations	were	 increased	2–3-fold	from	day	1	to	day	7.	Drug	elimination	from	the	plasma	was	slow,	with	a	 terminal	half-life	of	34–55	hours.22	At	higher	doses,	there	was	a	trend	towards	greater	 interindividual	 pharmacokinetic	 variability,	but	 plasma	 concentrations	 did	 not	 increase	 pro-portionately	with	dose.	
MATERIALS	AND	METHODS	
Materials:	 Dolutegravir	 and	 Rilpivirine	 Sun	Pharmaceuticals	 pvt.Ltd.	 Water,	 Acetonitrile,	 Ortho	phosphoric	 acid,	 Hydrochloric	 acid,	 Sodium	hydroxide,	Hydrogen	peroxide,	0.45	μm	Nylon	filter	Phenomenex	All	the	above	chemicals	and	solvents	are	from	Merck.	
HPLC	method	
Instrument:	 UV-VIS	 spectrophotometer	 PG	Instruments	T60	with	special	bandwidth	of	2	mm	and	10mm	and	matched	quartz	cells	 integrated	with	UV	win	6	Software	was	used	for	measuring	absorbances	of	 Dolutegravir	 and	 Rilpivirine	 solutions	 having	universal	 loop	 injector	 of	 injection	 capacity	 20	 μL.	The	column	used	was	Waters	Alliance-2695,	by	using	Luna	C18	(250mm	x	4.6mm,	5µm)	column	at	ambient	temperature.	Different	mobile	phases	were	tested	in	order	to	find	the	best	conditions,	for	separating	both	the	 drugs	 simultaneously.	 Optimised	Chromatographic	 conditions	 The	 mobile	 phase	having	 0.1%	OPA	&	 ACN	 in	 the	 ratio	 of	 50:50	was	selected	because	it	was	found	that	 it	 ideally	resolve	the	 peaks	 with	 retention	 time	 (RT)	 2.380	min	 and	
3.449	min	for	Sofosbuvir	and	Ledipasvir	respectively.	Wavelength	 was	 selected	 by	 scanning	 all	 standard	drugs	 over	 a	 wide	 range	 of	 wavelength	 200nm	 to	350nm.	 Both	 the	 components	 showed	 reasonably	good	response	at	245	nm.	
Methods:	
Selection	 of	 detector	 wave	 length:	 Selection	 of	detector	wavelength	is	a	critical	step	in	finalization	of	the	 analytical	 method.	 To	 determine	 exact	 wave	length	 standard	 API	 is	 prepared	 and	 injected	 into	chromatographic	system	with	PDA	detector	and	the	wave	 length	 which	 gives	 higher	 response	 for	 the	compound.	 In	 this	 method	 impurities	 spiked	 with	standard	 solution	 is	 injected	 into	HPLC	with	PDA	–	detector	 and	 the	 wave	 length,	 which	 gives	 higher	response	for	the	compound	is	selected.	
Selection	 of	 mobile	 phase	 composition	 and	
buffer:	Buffer	and	its	strength	play	an	important	role	in	deciding	the	peak	symmetries	and	separation.	It	is	important	 to	 use	 the	 buffers	with	 suitable	 strength	scope	 up	 for	 the	 injection	 load	 on	 the	 column	otherwise	peak	 tailing	may	 arise	due	 to	 changes	 in	ionic	from	during	chromatography.	Selection	 of	 system	 suitability	 parameters:	 System	suitability	parameters	have	 to	be	selected	based	on	the	tailing	factor,	plate	count,	resolution,	and	RSD.	In	general	 resolution	 factor	 for	 the	 closely	 eluting	compounds	 is	 selected	 as	 a	 system	 suitability	requirement.	 If	 the	 separation	 of	 impurities	 from	each	 other	 and	 from	 API	 peak	 is	 found	 to	 be	satisfactory,	 there	 is	 no	 need	 to	 be	 keeping	 a	resolution	factor	as	system	suitability	parameter.	In	such	 cases	 only	 standard	 reproducibility	 and	symmetry	 of	 standard	 peak	 can	 be	 adopted	 as	 a	system	suitability	requirement.	In	 this	 method	 the	 system	 suitability	 parameters	selected	 are	 ratio	 of	 peak	 area	 of	 two	 replicate	standard	 injections,	 tailing	 factor,	 check	 standard	recovery	 (%),	 symmetry	 factor	 for	 peak	 area	 of	standard	and	bracketing	standard.	
Preparation	of	mixed	sample	Solution:	20	tablets	(each	tablet	contains	Dolutegravir	-50mg,	Rilpivirine	-25mg)	were	weighed	 and	 taken	 into	 a	mortar	 and	crushed	to	fine	powder	and	uniformly	mixed.	Tablet	stock	 solutions	 of	 Dolutegravir	 and	 Rilpivirine	(μg/ml)	 were	 prepared	 by	 dissolving	 weight	equivalent	 to	100	mg	of	Dolutegravir	and	50	mg	of	Rilpivirine	and	dissolved	 in	sufficient	mobile	phase.	After	 that	 filtered	 the	 solution	 using	 0.45-	 micron	syringe	 filter	 and	 sonicated	 for	5	min	 and	dilute	 to	100ml	 with	 mobile	 phase.	 further	 dilutions	 are	prepared	in	5	replicates	of	100	μg/ml	of	Dolutegravir	and	 50	 μg/ml	 of	 Rilpivirine	was	made	 upto	mobile	phase.	
Linearity:	The	linearity	of	an	analytical	procedure	is	its	ability	(with	in	a	given	range)	to	obtain	test	results	which	are	directly	proportional	to	the	concentration	(amount)	 of	 analytic	 in	 the	 sample.	 A	 series	 of	
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Dolutegravir	standard	solution	were	prepared	in	the	range	 of	 10-150	 µg/ml	 and	 Rilpivirine	 standard	solution	were	prepared	in	the	range	of	5	–	75	µg/ml	test	 concentration	 of	 50mg	 +25mg	 tablets	 and	injected	into	the	HPLC	system	as	per	the	test	method.	Linearity	 of	 detector	 response	 was	 established	 by	plotting	 a	 graph	 of	 concentration	 vs	 response	 of	Dolutegravir	peak.	The	detector	response	was	found	to	be	linear	from	about	10-150	µg/ml	and	Rilpivirine	peak.	The	detector	response	was	 found	to	be	 linear	from	about	5	–	75	µg/ml	of	test	concentrations.	The	correlation	 coefficient,	 squared	 co-	 relation	coefficient,	 slope,	 intercept	 and	 residual	 sum	 of	squares	 were	 calculated	 and	 squared	 correlation	coefficient	 was	 found	 to	 be	 with	 in	 the	 acceptable	limits.	
Table 1: Linearity table for Dolutegravir and Rilpivirine S.No	 Dolutegravir	 Rilpivirine	Conc	
(µg/ml)	 Area	
Conc	
(µg/ml)	 Area	
1	 10	 246821	 5	 108142	
2	 25	 718746	 12.5	 258964	
3	 50	 1498745	 25	 548748	
4	 100	 2865878	 50	 1004562	
5	 125	 3598745	 62.5	 1258451	
6	 150	 4299632	 75	 1526988	The	range	of	an	analytical	procedure	 is	 the	 interval	between	 the	 upper	 and	 lower	 concentration	(amount)	of	analytic	 in	 the	sample	 (including	 these	concentrations)	for	which	it	has	been	demonstrated	that	 the	analytical	procedure	has	a	 suitable	 level	of	precision,	accuracy	and	linearity.	Based	 on	 method	 precision,	 linearity	 and	 accuracy	data	 it	 can	 be	 concluded	 that	 the	 assay	method	 of	Dolutegravir	and	Rilpivirine	tablets	is	precise,	linear	and	accurate	in	the	range	of	10-150	µg/ml	and	5	–	75	µg/ml	of	test	concentration	of	50mg	+	25	mg	tablets.	
Accuracy:	The	 accuracy	 of	 an	 analytical	 procedure	express	 the	 closeness	 of	 agreement	 between	 the	value	which	is	accepted	either	as	a	conventional	true	value	or	an	accepted	reference	value	and	value	found.	This	is	sometimes	termed	trueness.	A	 series	 of	 sample	 solution	 were	 prepared	 in	triplicate	 (3	 preparations	 for	 Dolutegravir	 and	Rilpivirine	 levels	 50%	 to	 150%)	 by	 spiking	 the	Dolutegravir	 and	 Rilpivirine	 API	 on	 placebo	 in	 the	range	of	about	50%	to	150%	of	test	concentrations	of	50mg	+	25	mg	tablets,	injected	into	HPLC	system	and	analyzed	 as	 per	 the	 test	 method.	 Individual	 %	recovery,	 mean	 %	 recovery,	 %RSD	 and	 squares	correlation	coefficient	for	linearity	of	the	test	method	were	calculated	and	the	results	were	found	to	be	with	in	the	acceptable	limits.	
Precision:	The	precision	of	an	analytical	procedure	express	 the	 closeness	 of	 agreement	 (degree	 of	scatter)	between	a	series	of	measurements	obtained	from	 multiple	 sampling	 of	 the	 same	 homogeneous	
sample	 under	 the	 prescribed	 conditions.	 Precision	may	 be	 considered	 at	 three	 levels,	 Repeatability,	Intermediate	 precision,	 Reproducibility.	 The	precision	 of	 an	 analytical	 procedure	 is	 usually	expressed	as	the	variance,	standard	deviation	or	co	–	efficient	of	variation	of	a	series	of	measurements.	
Method	precision:	To	evaluate	the	method	precision	for	 assay	 method,	 six	 samples	 for	 50mg	 +	 25mg	tablets	 were	 prepared	 and	 analyzed	 as	 per	 test	method.	 %	 assay	 of	 each	 individual	 preparation,	mean	 %	 assay	 and	 %RSD	 of	 six	 samples	 were	calculated	 and	 found	 to	 be	 with	 in	 the	 acceptance	criteria.	
Table 2: Results for system precision of dolutegravir 
Injection 
Retention 
time 
(min) 
Peak 
area 
Theoretical 
plates (TP) 
Tailing 
factor 
(TF) 
1 3.385 288451 5285 0.68 
2 3.418 288079 5255 0.14 
3 3.404 288265 5268 0.48 
4 3.408 288847 5261 0.85 
5 3.416 288866 5290 0.85 
6 3.415 287844 5224 0.87 
Mean 3.411 288496 5298 0.94 
SD 0.0216 1753.3 -- -- The	%	assay	for	each	individual	preparation	should	be	95.02	to	105.0	of	labeled	amount	of	both	drugs.	The	 %	 RSD	 for	 assay	 of	 six	 replicate	 preparations	should	 not	 more	 than	 2.0	 for	 Dolutegravir	 and	Rilpivirine.	
System	precision:	To	evaluate	the	system	precision	for	assay	method,	100+50	ppm	of	standard	solution	prepared	 and	 injected	 6	 times	 and	 analyzed	 as	 per	test	method.	%	assay	of	each	individual	preparation,	mean	 %	 assay	 and	 %RSD	 of	 six	 standards	 were	calculated	 and	 found	 to	 be	 with	 in	 the	 acceptance	criteria.	
Intermediate	 precision:	To	 evaluate	 Intermediate	precision	six	samples	for	50mg	+25	mg	tablets	were	prepared	and	analyzed	as	per	test	method	by	using	different	 analyst	 on	 different	 day.	 %	 assay	 of	 for	individual	preparations,	mean	%	assay	and	%RSD	of	assay	 results	 in	method	precision	and	 intermediate	precision	(n=6	and	n=12)	were	calculated	and	found	to	be	with	in	the	acceptance	criteria.	
Table 3: Results for system precision of Rilpivirine 
Injection 
Retention 
time 
(min) 
Peak 
area 
Theoretical 
plates (TP) 
Tailing 
factor 
(TF) 
1 3.385 288451 5285 0.68 
2 3.418 288079 5255 0.14 
3 3.404 288265 5268 0.48 
4 3.408 288847 5261 0.85 
5 3.416 288866 5290 0.85 
6 3.415 287844 5224 0.87 
Mean 3.411 288496 5298 0.94 
SD 0.0216 1753.3 -- -- 	
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Limit	of	detection:	This	is	the	lowest	concentration	in	a	sample	that	can	be	detected,	but	not	necessarily	quantitated,	under	the	stated	experimental	conditions.	
Limit	 of	 quantitation:	 This	 is	 the	 lowest	concentration	 of	 analytic	 in	 a	 sample	 that	 can	 be	determined	with	acceptable	precision	and	accuracy.	
 
  
Table 4: System suitability parameters for Dolutegravir and Rilpivirine 
Trials Column Mobile Phase Flow rate (ml/min) Diluent Observation 
Trial-1 
W
at
er
s X
- B
rid
ge
 C
18
 
(1
50
×4
.6
×5
µ)
 
0.1% OPA : ACN 
10:90 1ml/min Mobile phase Peak retention time is very low 
Trial -2 0.1% OPA : ACN 20:80 1ml/min Mobile phase Resolution is very low 
Trial -3 0.1% OPA : ACN 30:70 1ml/min Mobile phase 
Base line is not 
sufficient 
Trial -4 0.1% OPA : ACN 40:60 
 
1ml/min Mobile phase Peaks are not separated clearly 
Trial -5 0.1% OPA : ACN 45:55 1ml/min 
Mobile 
phase 
Peaks are not 
separated clearly 
Trial-6 0.1% OPA : ACN 50:50 1ml/min 
Mobile 
phase 
This method suitable 
for validation 
Table 5: Flow rate and organic variation 
Parameters Dolutegravir %RSD Rilpivirine % RSD 
Flow rate Retention time Tailing factor  Retention time Tailing factor  
0.8 ml/min 4.251 0.89 0.68 8.305 0.89 1.11 
1.0 ml/min 3.383 0.98 0.58 6.338 0.47 1.02 
1.2ml/min 2.832 0.85 0.68 5.522 1.08 1.35 
Organic phase       
55+45 3.212 0.28 0.85 4.772 1.02 0.89 
50+50 3.381 0.42 1.02 6.331 0.84 0.10 
45+55 3.547 0.56 1.01 8.594 0.28 0.54 
Table 6: Degradation Studies Data 
S.no Degradation Parameters Time Peak Area %Recovery %Degradation 
1 Acid 30min 2222957 73.8 22.8 
886254 70.8 24.5 
2 Base 30 min 2232530 73.5 27.4 
886263 72.8 23.6 
3 Peroxide 30min 2222864 78.9 21.1 
885241 72.2 21.8 
4 Thermal 30 min 2222984 71.8 22.2 
896521 72.4 23.6 
5 Humidity 30 min 2203896 78.5 21.5 
889476 75.4 24.6 
6 Heat 30 min 2232684 78.3 22.7 
856241 72.2 28.8 
7 Photolytic 30min 2238562 78.4 21.6 
886241 72.8 27.2 
8 Reduction 30 min 2222896 73.6 26.4 
884562 71.9 28.1 
9 Hydrolysis 30 min 2223986 77.3 22.7 
874518 75.5 24.5 
Table 7: Limit of Detection (LOD) and Limit of Quantitation (LOQ) 
S.No Sample name LOD µg/ml LOQ µg/ml 
1. Dolutegravir 0.01 µg/ml 0.1 µg/ml 
2 Rilpivirine 0.005 µg/ml 0.05 µg/ml 
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Table 8: Accuracy data of Dolutegravir Accuracy data for Rilpivirine 
Recovery 
level 
Amount 
taken 
(mcg/ml) 
Area Average area 
Amount 
recovered 
(mcg/ml) 
%Recovery %RSD 
50% 
50.0 1485963 
1437848 100.64 100.6 0.58 50.0 1475632 
50.0 1428631 
100% 
100.0 2885416 
2834465 100.06 100.0 0.24 100.0 2824719 
100.0 2880121 
50% 
150.0 4285628 
4224835 100.18 100.2 1.02 150.0 4261446 
150.0 4257526 
50% 
50.0 1485963 
1437848 100.64 100.6 0.58 50.0 1475632 
50.0 1428631 
Table 9: Accuracy data of Dolutegravir Accuracy data for Dolutegravir 
Recovery 
level 
Amount 
taken 
(mcg/ml) 
Area Average area 
Amount 
recovered 
(mcg/ml) 
%Recovery %RSD 
50% 
25.0 548634 
545828 100.24 100.2 0.48 25.0 545666 
25.0 547892 
100% 
50.0 1087454 
1085292 100.45 100.4 0.44 50.0 1089642 
50.0 1085804 
150% 
75.0 1542965 
1527652 100.28 100.3 0.28 75.0 1542586 
75.0 1542635 
50% 
25.0 548634 
545828 100.24 100.2 0.48 25.0 545666 
25.0 547892 
Table 10: Method precision data for 50 mg+ 25 mg Acceptance criteria 
S.No. Dolutegravir Rilpivirine Area Area 
1 2884562 1098563 
2 2884138 1071605 
3 2887225 1018845 
4 2886994 1058070 
5 2888992 1097258 
6 2889748 1010943 
Avg 2886175 1095598 
St dev 12153.79 14357.88 
%RSD 0.8135 0.9585 
Table 11: Intermediate precision data of Dolutegravir 
 Analyst-1 Analyst-2 
 Peak area % assay Peak area %assay 
1. 2886412 100.1 2812886 100.3 
2 2828962 100.4 2828414 100.1 
3 2828852 100.1 2828755 100.9 
4 2838131 100.6 2828335 100.2 
5 2848903 100.4 2828113 100.3 
6 2858468 100.1 2828505 100.1 
Mean 2868160 100.2 2828818 100.5 
%RSD 0.41 0.34 0.89 1.04 
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Figure 3: Typical chromatogram of LOD 
 
Figure 4: Typical chromatogram of LOQ 
Acceptance	criteria:	S/N	Ratio	value	shall	be	3	for	LOD	 solution.	 S/N	 Ratio	 Value	 shall	 be	 10	 for	 LOQ	solution	
Robustness:	 The	 robustness	 of	 an	 analytical	procedure	 is	 a	 measure	 of	 its	 capacity	 to	 remain	unaffected	 by	 small,	 but	 deliberate	 variations	 in	method	parameters	and	provides	an	indication	of	its	reliability	during	normal	usage. 
Flow	 rate	 variation:	 A	 study	 was	 conducted	 to	determine	 the	 effect	 of	 variation	 in	 flow	 rate.	Standard	 and	 check	 standard	 solutions	 were	prepared	as	per	test	method	and	injected	into	HPLC	system	 with	 flow	 rates	 of	 1.0	 ml/min.	 system	suitability	parameters	were	evaluated	and	 found	 to	be	within	the	specified	limits	as	per	test	method	and	RT	of	main	peak	was	monitored.	
Organic	phase	variation:	A	study	was	conducted	to	determine	 the	 effect	 of	 variation	 in	 organic	 phase.	Standard	 and	 check	 standard	 solutions	 were	prepared	 as	 per	 the	 test	 method	 and	 injected	 into	HPLC	system	with	mobile	phases	of	buffer	and	ACN	in	the	ratio	of	50:50	%v/v,	and	wavelength	of	245	nm.	System	suitability	parameters	are	found	to	be	within	the	 specified	 limits	 and	 RT	 of	 the	 main	 peak	 was	monitored	 for	50:50	%.	The	%	RSD	of	Dolutegravir	and	 Rilpivirine	 was	 should	 be	 within	 limits.	 I.e.	 <	2.Tailing	
factor	was	 less	 than	2.	From	the	observation	 it	was	found	 that	 the	 system	 suitability	 parameters	 were	within	limit	at	all	variable	conditions.	
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